Intuitive Surgical, Inc. Stock: +13.89% After Surpassing Quarterly Expectations
Intuitive Surgical's stock closed at $527.03 on Wednesday, October 22, marking a 13.89% increase from the previous session. This rise reflects the market's positive reception to the third-quarter results released that day. Trading volume reached 8.3 million shares, corresponding to 2.32% of the market capitalization. Over five sessions, the stock has accumulated a gain of 20.99%.
Stock Performance and Market Reaction
The 13.89% closing increase positions Intuitive Surgical among the top performers of the day. Over the week, the stock has gained 20.99%, indicating a renewed interest since the beginning of the week. Throughout the past year, the increase remains limited to 1.84%, reflecting a consolidation while the Nasdaq index has risen by 26.15% over the same period. The stock is therefore trading at a level lower than what the overall gains of the American market would justify. The intensity of the trades confirms the magnitude of the observed turnaround. The 8.3 million shares traded, representing 2.32% of the float, indicate sustained participation. This capital rotation reflects the operators' interest in the news announced on Wednesday. The company's market capitalization reaches approximately $189 billion, positioning Intuitive Surgical among the heavyweights of the medical sector. The valuation structure remains high. The expected 2025 price/earnings ratio stands at 69 times, while the 2025 enterprise value/revenue ratio reaches 18.4 times. These multiples reflect the market's expectations regarding the group's growth prospects. The 2026 price/earnings ratio drops to 60.8 times, suggesting that analysts anticipate an acceleration of profits.
Third Quarter Results Exceed Expectations
The third-quarter results surpassed consensus on both main lines. Revenue was $2.51 billion, exceeding the $2.40 billion estimate. Adjusted earnings per share reached $2.40, significantly above the forecast of $1.98, revealing better control of operational profitability. Growth stems from an acceleration in the use of da Vinci systems. Procedures performed with these surgical robots have increased by about 20% year-over-year. The number of systems installed during the quarter reached 427 units, up from 379 the previous year, indicating an increasing penetration of the technology in hospitals. The cumulative installed base now stands at 10,763 systems, up 13% year-over-year. The Ion division, the group's endoscopic segment, is rapidly progressing. The installed base of this equipment has increased by 30% to 954 systems, marking an effective diversification beyond surgical robotics. Intuitive Surgical also rolled out new software features for its da Vinci 5 platform in September, aimed at enhancing surgeons' performance and the efficiency of facilities. For the year 2025, management has slightly raised its guidance. The expected growth in da Vinci procedures is set between 17% and 17.5%, against a previous range of 15.5% to 17%. The impact of tariffs has also been revised downward, from 1% of revenue to 0.7%, mitigating the risks of commercial heaviness. The 2025 gross margin is expected to be between 67% and 67.5%, slightly down from the 69.1% achieved in 2024.
Bernstein's Analysis Supports Positive Outlook
Bernstein's analysis supports this constructive scenario. The research firm has maintained its buy recommendation and raised its price target to $700 from $685 previously, implying an additional increase of about 33% from current levels.
